RecallDepth
Class II Ongoing

Tri-Moxi+¿ (Triamcinolone 9mg/0.6mL, Moxifloxacin 0.6 mg/ 0.6 mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852. NDC 71384-746-06.

This recall is currently active, issued January 14, 2026. It was issued by Imprimis Njof, Llc.

Company
Imprimis Njof, Llc
Recall Initiated
December 18, 2025
Posted
January 14, 2026
Recall Number
D-0251-2026
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
314 boxes of 6,280 pre-filled syringes
Firm Location
Ledgewood, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

Presence of particulate matter - Glass like particles.

Distribution

U.S Nationwide

Lot / Code Info

Lot: 25JAN033A, 25JAN033B, Expires: 02/12/2026.

More recalls by Imprimis Njof, Llc

View all recalls by this company →

Other recent Class II Drug recalls